Baxalta Ventures
6
20M
3
1.00
2
0.50
2
- Areas of investment
Summary
Baxalta Ventures is the famous VC, which was founded in 2015. The leading representative office of defined VC is situated in the Cambridge. The fund was located in North America if to be more exact in United States. Baxalta Ventures seemed to be an CVC arrangement as part of the organization.
The overall number of key employees were 1.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Syntimmune, Gadeta, True North Therapeutics The fund has exact preference in some founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Clinical Trials, Health Care.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Baxalta Ventures, startups are often financed by Partners Innovation Fund, Apple Tree Partners, SR One. The meaningful sponsors for the fund in investment in the same round are Partners Innovation Fund, Apple Tree Partners, Utrecht Holdings. In the next rounds fund is usually obtained by Partners Innovation Fund, Apple Tree Partners, SR One.
Opposing the other organizations, this Baxalta Ventures works on 4 percentage points more the average amount of lead investments. The top activity for fund was in 2016. The higher amount of exits for fund were in 2018. The fund is constantly included in less than 2 deals per year. Considering the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund.
Investments analytics
Analytics
- Total investments
- 6
- Lead investments
- 2
- Exits
- 2
- Rounds per year
- 1.00
- Follow on index
- 0.50
- Investments by industry
- Biotechnology (6)
- Medical (5)
- Health Care (5)
- Pharmaceutical (4)
- Emergency Medicine (4) Show 2 more
- Investments by region
-
- United States (5)
- Netherlands (1)
- Peak activity year
- 2016
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Avg. valuation at time of investment
- 533M
- Group Appearance index
- 1.00
- Avg. company exit year
- 4
- Avg. multiplicator
- 7.34
- Strategy success index
- 0.71
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| True North Therapeutics | 03 Dec 2015 | Biotechnology, Health Care, Clinical Trials | Late Stage Venture | 40M | United States, California, South San Francisco |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.